ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Important new insights from a post-hoc analysis of the RENOVE randomized trial, evaluating safety during extended treatment (after ≥6 months of full-dose therapy) with apixaban or rivaroxaban by Prof Francis COUTURAUD
Key Findings (5-year outcomes):
• Clinically relevant bleeding (CRB): Similar between drugs at both full and reduced doses.
• Major bleeding: No significant differences across subgroups.
• Recurrent VTE: Low and comparable with both agents.
• Dose reduction: Consistently lowered CRB risk for both apixaban and rivaroxaban.
Takeaway:
Unlike early-treatment data where rivaroxaban shows higher bleeding risk, during extended therapy the safety profiles of apixaban and rivaroxaban appear equivalent. More trials are needed.”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 10:36Cynthia Dunbar: Retiring From NIH After 39 Years to Advance Advocacy and Research in Hematology
-
Mar 11, 2026, 23:05Ney Carter Borges: A Safety Advantage of Apixaban over Rivaroxaban Without Clear Superiority
-
Mar 11, 2026, 22:01The Results of Landmark COBRRA Trial in Acute VTE Management – ISTH
-
Mar 11, 2026, 21:19Peter Antevy: EMS Rarely Suspects Pediatric Stroke And It’s Costing Kids Time
-
Mar 11, 2026, 19:24Robert Sidonio: Prophylaxis with Wilate and The WIL-31 Study Results
-
Mar 11, 2026, 18:42Annette Logan-Parker: A Hemophilia B Breakthrough – From Weekly Infusions to One Treatment
-
Mar 11, 2026, 18:27Cesar Garrido and Lackram Bodoe Are Advancing WFH Partnerships in Trinidad and Tobago
-
Mar 11, 2026, 18:14Aloke Finn: Silent Plaque Rupture and Healing in Coronary Artery Disease
-
Mar 11, 2026, 17:23Mattia Galli: A Privilege to Collaborate on Such a Complex Topic as Cardio-Rheumatology